A Phase 1/2 Study of Etentamig in Combination with a CELMoD Agent for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma

Status

Recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512146-41-00

Acronym

M24-555

Enrollment

Registered

2025-07-08

Start date

2025-07-29

Completion date

Unknown

Last updated

2025-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Brief summary

Dose-limiting toxicities (DLT) of etentamig when given in combination with Iberdomide in subjects with Relapsed/Refractory Multiple Myeloma.

Detailed description

Response rate (RR): Partial Response (PR), Very Good Partial Response (VGPR), Complete Response (CR), stringent Complete Response (sCR), Overall Response Rate (ORR), Progression-free survival (PFS), Duration of response (DOR), Time-to-progression (TTP), Minimal Residual Disease (MRD) negativity

Interventions

DRUGIberdomide

DRUGABBV-383

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Dose-limiting toxicities (DLT) of etentamig when given in combination with Iberdomide in subjects with Relapsed/Refractory Multiple Myeloma.	—

Secondary

Measure	Time frame
Response rate (RR): Partial Response (PR), Very Good Partial Response (VGPR), Complete Response (CR), stringent Complete Response (sCR), Overall Response Rate (ORR), Progression-free survival (PFS), Duration of response (DOR), Time-to-progression (TTP), Minimal Residual Disease (MRD) negativity	—

Countries

France, Netherlands, Norway

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026